Related Experiment Video
Updated: Apr 17, 2026
Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
NUT midline carcinoma
1Department of Pathology, Brigham and Women's Hospital, harvard Medical School, 75 Francis Street, Boston, Massachusetts, 02115, USA. cfrench@partners.org
Abstract:
NUT midline carcinoma, a squamous cell carcinoma, is one of the most aggressive human cancers, and there is a desperate need for effective therapies for patients with this disease. Will the new bromodomain and extra terminal (BET) inhibitors prove to be one such treatment for this rare and enigmatic cancer?
Insights
NUT midline carcinoma is a highly aggressive cancer lacking effective treatments. Researchers are investigating whether novel bromodomain and extra terminal (BET) inhibitors could offer a new therapeutic option for this rare disease.
Area of Science:
- Oncology
- Cancer Biology
- Pharmacology
Background:
- NUT midline carcinoma (a type of squamous cell carcinoma) is exceptionally aggressive.
- There is a critical unmet need for effective therapies for patients diagnosed with this rare cancer.
Purpose of the Study:
- To evaluate the potential of novel bromodomain and extra terminal (BET) inhibitors as a therapeutic strategy.
- To explore new treatment avenues for NUT midline carcinoma.
Main Methods:
- Investigational study of BET inhibitors.
- Analysis of therapeutic efficacy in preclinical models (details not provided in abstract).
Main Results:
- Results are pending or not detailed in the provided abstract.
- The study aims to determine if BET inhibitors show promise.
Conclusions:
- The potential of BET inhibitors for treating NUT midline carcinoma requires further investigation.
- This research seeks to address the urgent need for novel therapeutic interventions.
